Why is AbbVie stock up 1.8% today?

Traders Union
All News
Stocks
AbbVie rises 1.82% today on FDA gains

Highlights

AbbVie received two FDA Breakthrough Therapy Designations for telisotuzumab adizutecan and reported 10.2% year-over-year revenue growth to $16.99 billion in the second quarter of 2026.
The company completed a $10.9 billion agreement to acquire Apogee Therapeutics, expanding its pipeline with the IL-13 antibody zumilokibart, and declared a dividend of $1.73 per share.
Shares of AbbVie trade at $277.37 in a strong uptrend with overbought signals, expected to fluctuate between $270.04 and $284.83 in the next five trading days.

Pipeline expansion and trial results drive sentiment after new designations

AbbVie recently received two FDA Breakthrough Therapy Designations for telisotuzumab adizutecan targeting colorectal cancer and non-small cell lung cancer, based on the M21-404 clinical study data. The company reported positive Phase 3 results for epcoritamab plus R-CHOP in diffuse large B-cell lymphoma and second quarter 2026 revenue of $16.99 billion, a 10.2% increase year-over-year, with a dividend of $1.73 per share declared. AbbVie also entered an agreement to acquire Apogee Therapeutics for $10.9 billion, adding the IL-13 antibody zumilokibart to its pipeline. Additional approvals include Juvmo for Parkinson’s disease in the US and Rinvoq for pediatric arthritis in Europe.

Anton Kharitonov, expert at Traders Union, notes that AbbVie’s recent rally is driven by positive FDA developments and robust momentum. He sees the technical signals as strong but highlights clear overbought readings from the RSI, CCI, and Stochastic RSI. Kharitonov remains cautious about sustainability, especially near resistance at $284.83. He points out rising volatility risk given the rapid ascent and crowded bullish positioning. "The setup favors bulls for now, but such crowded longs in overbought territory expose the stock to sharp profit-taking and short-term pullbacks," he warns.

Viktoras Karapetjanc, expert at Traders Union, believes AbbVie’s ongoing gains reflect strong investor confidence in its pipeline achievements. He sees clear catalysts in the dual FDA Breakthrough Therapy Designations and a solid revenue trajectory from recent results. Karapetjanc emphasizes that the bullish structure remains intact above support, with further growth expected if $284.83 is broken. "With expanding oncology assets and proven earnings momentum, the market offers multiple setups for ongoing upside in AbbVie," he says.

Sholanke Dele, market strategist, sees the current uptrend in AbbVie as overextended by short-term sentiment. He highlights that overbought technicals and narrow intraday ranges signal possible exhaustion. Dele remains skeptical about chasing at current levels after such a concentrated rally. "I remain defensive here — the stock looks vulnerable to a corrective swing as bullish momentum fades," he states.

Overbought signals emerge as bullish structure nears resistance

AbbVie is trading well above its 20-day ($264.33), 50-day ($258.5), and 200-day ($232.41) moving averages, indicating sustained bullish momentum in short-, medium-, and long-term trends. The technical structure is reinforced by a bullish alignment between the 50-day and 200-day averages, with near-term resistance seen at $284.83 and support at $274.94. Momentum readings are positive, as the MACD trends up, though the ADX highlights only modest trend strength. The RSI is elevated at 66.39 and the CCI stands at 185.98, both flagging overbought conditions. The Stochastic RSI is fully overbought at 100, suggesting possible exhaustion, with Bull/Bear Power at 6.45 indicating buyers are in control within an overbought regime. The Awesome Oscillator supports the ongoing uptrend. AbbVie trades at $277.37, positioning close to the session's high within a narrow $270.44–$271.53 intraday range, and volatility at 0.40%. Overall, momentum signals and intraday price action confirm persistent buying and strength toward the session highs.

Earlier, analysts noted that AbbVie's clinical and regulatory progress was supporting a sustained bullish trend, though overbought technical conditions warranted caution. The current article reinforces this constructive outlook with fresh upside momentum and confirms that a break above $284.83 could unlock further gains, while attention should remain on $270.04 as a pivotal downside level.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.